Immunome
IMNM
30 hedge funds and large institutions have $9.34M invested in Immunome in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
93% more capital invested
Capital invested by funds: $4.85M → $9.34M (+$4.5M)
7% more funds holding
Funds holding: 28 → 30 (+2)
2.1% less ownership
Funds ownership: 17.32% → 15.22% (-2.1%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
70% less call options, than puts
Call options by funds: $49K | Put options by funds: $163K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$732K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$82.3K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$75.5K |
| 4 |
Renaissance Technologies
New York
|
+$38.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
-$1.72M |
| 2 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
-$324K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$46.5K |
| 4 |
N
Natixis
Paris,
France
|
-$39.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $9.25K | +$5 | +1 | +0.1% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $7K | -$5.04K | -1,030 | -44% |
|
|
NFSG
28
Newbridge Financial Services Group
Boca Raton,
Florida
| $1.87K | – | – | – |
|
|
FFA
29
Farther Finance Advisors
San Francisco,
California
| $499 | – | – | – |
|
30
UBS Group
Zurich,
Switzerland
| $70 | -$2.25K | -460 | -97% |
|
31
Osaic Holdings
Scottsdale,
Arizona
| – | -$3K | -1,229 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$24 | -11 | Closed |
|
IMNM Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2023, worth a combined $9.34M — up 93% from $4.85M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IMNM positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $732K. The largest seller was Alpine Global Management, cutting an estimated $1.72M.
- 30 institutional investors held Immunome (IMNM) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $9.34M of Immunome stock for Q1 2023, up 93% quarter-over-quarter.
- 4 funds opened new Immunome positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Immunome buyer in Q1 2023 was Millennium Management, an estimated $732K added.
- The largest Immunome seller in Q1 2023 was Alpine Global Management, an estimated $1.72M sold.
Based on aggregated 13F filings for Q1 2023.